Compare YJ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 1.7M |
| IPO Year | 2019 | 2021 |
| Metric | YJ | VRAX |
|---|---|---|
| Price | $1.85 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 6.8K | ★ 157.1K |
| Earning Date | 04-20-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.17 |
| 52 Week High | $2.67 | $1.34 |
| Indicator | YJ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 37.27 |
| Support Level | $1.70 | N/A |
| Resistance Level | $2.18 | $0.25 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 96.08 | 2.59 |
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.